<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27629368</article-id>
<article-id pub-id-type="pmc">5143501</article-id>
<article-id pub-id-type="pii">npp2016199</article-id>
<article-id pub-id-type="doi">10.1038/npp.2016.199</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuropsychopharmacology Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders</article-title>
<alt-title alt-title-type="running">Inflammation, glutamate, and glia</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Haroon</surname>
<given-names>Ebrahim</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8817-1116</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Andrew H</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sanacora</surname>
<given-names>Gerard</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</institution>, Atlanta, GA, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Psychiatry, Yale University School of Medicine</institution>, New Haven, CT, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</institution>, 101 Woodruff Circle, Suite 6001, Atlanta, GA 30322, <country>USA</country>, Tel: +404 712 2890, Fax: +404 727 3233, E-mail: <email>eharoon@emory.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>15</day>
<month>09</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>42</volume>
<issue>1</issue>
<fpage>193</fpage>
<lpage>215</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>06</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>05</day>
<month>09</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>09</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2017 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Increasing data indicate that inflammation and alterations in glutamate neurotransmission are two novel pathways to pathophysiology in mood disorders. The primary goal of this review is to illustrate how these two pathways may converge at the level of the glia to contribute to neuropsychiatric disease. We propose that a combination of failed clearance and exaggerated release of glutamate by glial cells during immune activation leads to glutamate increases and promotes aberrant extrasynaptic signaling through ionotropic and metabotropic glutamate receptors, ultimately resulting in synaptic dysfunction and loss. Furthermore, glutamate diffusion outside the synapse can lead to the loss of synaptic fidelity and specificity of neurotransmission, contributing to circuit dysfunction and behavioral pathology. This review examines the fundamental role of glia in the regulation of glutamate, followed by a description of the impact of inflammation on glial glutamate regulation at the cellular, molecular, and metabolic level. In addition, the role of these effects of inflammation on glia and glutamate in mood disorders will be discussed along with their translational implications.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>